In recent years, mRNA technology enabled the rapid development of vaccines to fight COVID-19, saving millions of lives.

Q4 2024 Earnings Call Transcript April 10, 2025 CureVac N.V. misses on earnings expectations. Reported EPS is $-0.16564 EPS, ...

In this webinar, Benoit Derrien will discuss new strategies using enzymatically synthesized DNA for gene construction.

A review paper published last year in European Journal of Medicinal Chemistry characterized Myc as the “oncogene from ...

Hapatune LLC, a leading global marketing boutique for bioprocess and life science tools and service providers, today ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

Decoy’s development of novel peptide-conjugate therapeutics arising from its proprietary IMP3ACT™ platform to benefit from Dr ...

“Larger mRNA-based therapeutics are synthesised by ... machine learning approaches to utilise datasets to inform design of new materials and compositions.” Further, the company will also ...

CureVac will be responsible for mRNA design, formulation and manufacturing of clinical supply and retains the option to co-promote the vaccine products in Germany. The new deal adds to CureVac ...